CX Institutional Trims Holdings in Gilead Sciences, Inc. $GILD

CX Institutional trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 56.7% during the second quarter, HoldingsChannel.com reports. The firm owned 58,297 shares of the biopharmaceutical company’s stock after selling 76,191 shares during the quarter. CX Institutional’s holdings in Gilead Sciences were worth $7,365,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in GILD. Aviva PLC grew its position in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new position in shares of Gilead Sciences in the fourth quarter worth $1,418,000. NBC Securities Inc. raised its position in shares of Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Gilead Sciences by 43.9% in the fourth quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company’s stock worth $6,973,000 after buying an additional 17,325 shares in the last quarter. Finally, Flputnam Investment Management Co. boosted its stake in Gilead Sciences by 66.5% during the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock valued at $12,978,000 after buying an additional 42,243 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 67,000 shares of company stock worth $8,687,140. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on GILD shares. Morgan Stanley reduced their target price on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Citigroup boosted their price objective on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Gilead Sciences in a research report on Wednesday, July 29th. Finally, The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $157.93.

Gilead Sciences Stock Up 0.7%

Shares of NASDAQ:GILD opened at $131.15 on Tuesday. The firm has a market capitalization of $162.83 billion, a PE ratio of 17.87 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The firm has a fifty day moving average of $129.55 and a 200 day moving average of $136.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the business posted $1.81 earnings per share. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.